Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M C Jockers-Scherübl

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Lancet (London, England)|November 6, 2007
Cannabis and psychosisO Schulte-Herbrüggen, M C Jockers-Scherübl
Journal of Neural Transmission (Vienna, Austria : 1996)|March 3, 2004
State of the art of the neurotrophin hypothesis in psychiatric disorders: implications and limitationsU E Lang, M C Jockers-Scherübl, R Hellweg
Lancet (London, England)|April 6, 1996
Is nerve growth factor a serum marker for neurological and psychiatric complications in Behcet's disease?M C Jockers-Scherübl, C C Zouboulis, F Boegner, et al.
European Journal of Biochemistry|March 15, 1989
Trypanothione reductase from Trypanosoma cruzi. Catalytic properties of the enzyme and inhibition studies with trypanocidal compoundsM C Jockers-Scherübl, R H Schirmer, R L Krauth-Siegel
Pharmacopsychiatry|February 3, 2006
Massive creatine kinase elevations with quetiapine: report of two casesJ P Klein, U Fiedler, H Appel, et al.
Current Medicinal Chemistry|September 28, 2007
Neurotrophic factors--a tool for therapeutic strategies in neurological, neuropsychiatric and neuroimmunological diseases?O Schulte-Herbrüggen, A Braun, S Rochlitzer, et al.
Biochemical Society Transactions|April 1, 1989
NADPH-dependent disulphide reductasesR L Krauth-Siegel, M C Jockers-Scherübl, K Becker, et al.
Pharmacopsychiatry|August 19, 2007
Electroconvulsive monotherapy in confusion psychosis: a potential standard regimen?A H Neuhaus, A Luborzewski, C Opgen-Rhein, et al.
Pharmacopsychiatry|December 13, 2005
Electroconvulsive monotherapy in the treatment of acute confusion psychosis. A case reportA H Neuhaus, J Katchanov, C Opgen-Rhein, et al.
International Clinical Psychopharmacology|December 17, 2004
Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: a double-blind placebo-controlled studyM C Jockers-Scherübl, A Bauer, F Godemann, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Lancet (London, England)|November 6, 2007
Cannabis and psychosisO Schulte-Herbrüggen, M C Jockers-Scherübl
Journal of Neural Transmission (Vienna, Austria : 1996)|March 3, 2004
State of the art of the neurotrophin hypothesis in psychiatric disorders: implications and limitationsU E Lang, M C Jockers-Scherübl, R Hellweg
Lancet (London, England)|April 6, 1996
Is nerve growth factor a serum marker for neurological and psychiatric complications in Behcet's disease?M C Jockers-Scherübl, C C Zouboulis, F Boegner, et al.
European Journal of Biochemistry|March 15, 1989
Trypanothione reductase from Trypanosoma cruzi. Catalytic properties of the enzyme and inhibition studies with trypanocidal compoundsM C Jockers-Scherübl, R H Schirmer, R L Krauth-Siegel
Pharmacopsychiatry|February 3, 2006
Massive creatine kinase elevations with quetiapine: report of two casesJ P Klein, U Fiedler, H Appel, et al.
Current Medicinal Chemistry|September 28, 2007
Neurotrophic factors--a tool for therapeutic strategies in neurological, neuropsychiatric and neuroimmunological diseases?O Schulte-Herbrüggen, A Braun, S Rochlitzer, et al.
Biochemical Society Transactions|April 1, 1989
NADPH-dependent disulphide reductasesR L Krauth-Siegel, M C Jockers-Scherübl, K Becker, et al.
Pharmacopsychiatry|August 19, 2007
Electroconvulsive monotherapy in confusion psychosis: a potential standard regimen?A H Neuhaus, A Luborzewski, C Opgen-Rhein, et al.
Pharmacopsychiatry|December 13, 2005
Electroconvulsive monotherapy in the treatment of acute confusion psychosis. A case reportA H Neuhaus, J Katchanov, C Opgen-Rhein, et al.
International Clinical Psychopharmacology|December 17, 2004
Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: a double-blind placebo-controlled studyM C Jockers-Scherübl, A Bauer, F Godemann, et al.
Pageof 2